Brief: NeuroMetrix Reports Results From Pilot Clinical Trial Of Quell In Post-Acute Covid-19 Syndrome
12/12/2023 14:07
Dec 12 (Reuters) - NeuroMetrix Inc NURO.O :
* NEUROMETRIX REPORTS ENCOURAGING RESULTS FROM PILOT
CLINICAL
TRIAL OF QUELL® IN POST-ACUTE COVID-19 SYNDROME (LONG COVID)
Source text for Eikon: ID:nGNX2XR379
Further company coverage: NURO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NeuroMetrix
See all newsBrief: Neurometrix To Be Acquired By Electrocore
Brief: Neurometrix Reiterates Its Review Of Strategic Alternatives
Brief: NeuroMetrix Announces Steps Taken To Enhance Shareholder Value
Brief: Ephraim Fields Reports 9.3% Stake In Neurometrix, Inc. As Of Feb 23, 2024 - SEC Filing
Brief: RS Fund Reports 14.4% Stake In Neurometrix Inc As Of Feb 13